HER-2-targeted therapy in well-selected HER-2-positive (IHC—Immunohistochemstry—3 positive or 2 positive with FISH—fluorescence in situ hybridization—positive) gastric cancer has successfully improved the survival of such patients in a phase III trial [11]. The gene discussed is ERBB2; the disease is gastric cancer.